New Strategies Needed As China Shakes Up Drug Classes?
This article was originally published in PharmAsia News
Executive Summary
In a fundamental shakeup of chemical drug classifications in China, foreign imported products are now in a class of their own while domestic drugs will be considered generics unless they are NCEs or have new formulations or indications. The changes are set to change the competitive landscape in profound ways, industry observers predict.